The KDM3A antibody is a crucial tool in studying the KDM3A protein, a member of the lysine demethylase (KDM) family. KDM3A, also known as JMJD1A, is a histone demethylase that specifically removes methyl groups from histone H3 lysine 9 (H3K9me1/me2), playing a key role in epigenetic regulation. It is involved in diverse biological processes, including transcriptional activation, metabolic homeostasis, spermatogenesis, and stress response. Dysregulation of KDM3A has been linked to cancers (e.g., prostate, liver, and colorectal cancers), infertility, and metabolic disorders, making it a potential therapeutic target.
The KDM3A antibody enables researchers to detect and quantify KDM3A expression in tissues or cells via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). It also facilitates chromatin immunoprecipitation (ChIP) to study KDM3A’s genome-wide binding sites and its interaction with chromatin. Commercial KDM3A antibodies are typically validated for specificity and sensitivity, often targeting conserved regions like the catalytic Jumonji domain. Recent studies using these antibodies have revealed KDM3A’s role in tumor progression, hypoxia adaptation, and stem cell differentiation. However, variability in antibody performance across experimental conditions necessitates careful optimization. Ongoing research continues to explore KDM3A’s functional mechanisms and its implications in disease, driving demand for reliable antibodies in both basic and translational studies.